Eli Lilly and Pfizer have announced top-line results from a phase III study evaluating tanezumab in the management of osteoarthritis.
The study is one of six involving approximately 7000 patients in which tanezumab was administered in 2.5mg or 5mg doses and evaluated every eight weeks for a total of 24 weeks. Tanezumab is part of a class of non-opioid pain medications, more commonly known as nerve growth factor inhibitors.
Lilly has stated that the medication clearly delivered a statistically significant improvement in pain.
Christi Shaw, president of Lilly Biomedicines said: “For many people, living with osteoarthritis pain can limit their ability to function, which can force them to make compromises in everyday life.
“Lilly and Pfizer have a shared commitment to advance the care of people living with chronic pain, and we can see the potential of Tanezumab as an innovative, non-opioid to improve the treatment of osteoarthritis pain, a debilitating, progressive condition.”
Currently there are over 27 million Americans living with osteoarthritis, a condition that can be life-altering as well as having debilitating physical, emotional and social effects.